Mainstream

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Post ContentalnyRead More

You might also be interested in reading Ethereum ETFs Inflow Streak Sets Up ETH for New Lifetime Highs, Traders Say.

February 14, 2025
In Mainstream